RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hodgkin lymphoma: maintenance drug after transplant
Disease control Recruiting nowThis study tests whether a drug called a PD-1 inhibitor can help keep Hodgkin lymphoma from coming back after a stem cell transplant. It is for people whose lymphoma returned or did not respond to earlier treatments. About 83 adults will receive the drug as maintenance therapy an…
Matched conditions: RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: St. Petersburg State Pavlov Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for hodgkin lymphoma: drug combo aims to boost transplant success
Disease control Recruiting nowThis phase 2 trial tests whether combining two drugs, pembrolizumab and brentuximab vedotin, can better shrink or eliminate Hodgkin lymphoma compared to standard chemotherapy (GDP) before a stem cell transplant. About 84 adults with relapsed or refractory classical Hodgkin lympho…
Matched conditions: RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC